Abstracts tagged "body mass"

Abstract Number: 0395 • ACR Convergence 2022
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Juergens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Christina Budden⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, ⁴Medizinische Hochschule Hannover, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany
Background/Purpose: There is a higher prevalence of obesity in patients (pts) with psoriatic disease1. The German non-interventional study AQUILA provides real-world data on the influence…
Abstract Number: 0405 • ACR Convergence 2022
Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Baseline BMI: A Post Hoc Analysis of Phase 2 and Phase 3 Trials
Hillary Norton¹, Paula Sliwinska-Stanczyk², Tomas Hala³, Bassel Elzorkany⁴, Lori Stockert⁵, Harry Shi⁵, Cunshan Wang⁶, Jerome Paulissen⁷ and Christopher Ritchlin⁸, ¹Sante Fe Rheumatology, Santa Fe, NM, ²Reumatika Centrum Reumatologii, Warsaw, Poland, ³Center for Clinical and Basic Research, Pardubice, Czech Republic, ⁴Department of Rheumatology, Cairo University, Cairo, Egypt, ⁵Pfizer, Inc, Collegeville, PA, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, New York, NY, ⁸Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY
Background/Purpose: Higher BMI is associated with reduced response to TNF inhibitors (TNFi) in patients (pts) with AS.1 Tofacitinib is an oral Janus kinase inhibitor for…
Abstract Number: 0125 • ACR Convergence 2021
Body Mass Composition in Post-menopausal Women with Fibromyalgia: Preliminary Results from a Cross-sectional Monocentric Study
Sabrina Paolino¹, Elvis Hysa², MASCARO ROSSELLA³, Andrea Casabella¹, LUCA CARMISCIANO⁴, Emanuele Gotelli¹, Carmen Pizzorni⁵, Alberto Sulli¹, Vanessa Smith⁶ and Maurizio Cutolo¹, ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology Department of Internal Medicine University of Genova Italy IRCCS Polyclinic San Martino, Genoa, Italy, ³Laboratory od Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Italy - IRCCS Rheumatology Unit San Martino Polyclinic, Genoa, Italy, ⁴Department of Health Sciences ( DISSAL), Section of Biostatistics, University of Genova, Genova, Italy, ⁵Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Dept. Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ⁶Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent, Belgium
Background/Purpose: Fibromyalgia (FM) is characterized by chronic musculoskeletal widespread pain, fatigue, sleep disturbances and functional symptoms. The primary endpoint of our study aimed to determine…
Abstract Number: 1229 • ACR Convergence 2021
Does BMI Influence the Efficacy of Subcutaneous or Intravenous Abatacept in Patients with RA in Routine Clinical Practice? A Post Hoc Analysis of Two Real-world Observational Studies
Rieke Alten¹, Xavier Mariette², Melanie Chartier³, Christiane Rauch⁴, Yedid Elbez⁵, Karissa Lozenski⁶ and Vadim Khaychuk⁶, ¹Schlosspark-Klinik University, Berlin, Germany, ²Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, ³Bristol Myers Squibb, Rueil-Malmaison, France, ⁴Bristol Myers Squibb, Munich, Germany, ⁵Deepscover, Puteaux, France, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: BMI has been shown to affect treatment response and may influence the development of optimal individualized treatment plans in patients with RA.1 The extent…
Abstract Number: 0108 • ACR Convergence 2020
The Relationship Between Body Fat Percentage and Bone Mineral Density in Rheumatoid Arthritis Patients
Anastasia- Vasiliki Madenidou¹ and Marwan Bukhari², ¹Rheumatology Department, University Hospitals of Morecambe Bay NHS Trust, Barrow-in-Furness, United Kingdom, ²Rheumatology Department, University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom
Background/Purpose: Currently, Dual-Energy X-ray Absorptiometry (DEXA) scans are used to determine fracture risk by calculating Bone Mineral Density (BMD). It is well established that body…
Abstract Number: 0776 • ACR Convergence 2020
The Influence of Adipokine Profile and Periodontal Infection in Early Stages of Rheumatoid Arthritis and First-degree Relatives
Consuelo Romero-Sanchez¹, Juliette De Avila², Jeimmy Andrea Chaparro-Sanabria³, Philipe Chalem Choueka⁴, Juan Manuel Bello-Gualtero⁵, Alejandro Ramos-Casallas², Lorena Chila-M² and Wilson Bautista-Molano⁶, ¹Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada / Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada /Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ²Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ³Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, ⁴Fundacion Instituto de Reumatología Fernando Chalem, Universidad El Rosario, Bogotá D.C., Colombia, ⁵Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada/ Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, ⁶University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia
Background/Purpose: Early RA (eRA) patients have a significant incidence of periodontal inflammation and overweight/obesity. A similar degree of disease activity, functional disability and health-related quality…
Abstract Number: 1203 • ACR Convergence 2020
Analysis of the Impact of Tofacitinib Treatment on Weight in Patients with Rheumatoid Arthritis
Jürgen Wollenhaupt¹, Jacques Morel², Claire Daien³, Adeline Ruyssen-Witrand⁴, Cédric Lukas³, Christophe Richez⁵, Andrea Shapiro⁶, Douglass S Chapman⁷, Magali Cros⁸, Jose L Rivas⁹ and Gustavo Citera¹⁰, ¹Struenseehaus Centre for Rheumatology and Clinical Immunology, Hamburg, Germany, ²Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France, ³CHU Montpellier and University of Montpellier, Montpellier, France, ⁴Hôpital Purpan, CHU Toulouse, Toulouse, France, ⁵Groupe Hospitalier Pellegrin-CHU de Bordeaux, Bordeaux, France, ⁶Pfizer Inc, Peapack, NJ, ⁷Pfizer Inc, New York, NY, ⁸Pfizer Inc, Paris, France, ⁹Pfizer SLU, Madrid, Spain, ¹⁰Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: A prior post hoc analysis of tofacitinib clinical trial data reported improvements in RA outcomes with tofacitinib vs placebo (PBO) through Month (M)6, regardless…
Abstract Number: 1207 • ACR Convergence 2020
Impact of Body Mass Index on Clinical Responses of Novel Subcutaneous Infliximab (CT-P13 SC) in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Part 2 of Phase I/III Randomized Controlled Trial
DaeHyun Yoo¹, Rene Westhovens², Piotr Wiland³, Marek Zawadzki⁴, Delina Ivanova⁵, Alfredo Berrocal Kasay⁶, Elias Chalouhi⁷, Eva Balázs⁸, SangJoon Lee⁹, SungHyun Kim⁹, NooRi Han⁹ and YooBin Jung⁹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²University Hospitals Leuven, Belgium, Leuven, Belgium, ³Medical Univeristy, Wroclaw, Poland, ⁴Medical Univeristy, Dpt of Rheumatology , Wroclaw, Wroclaw, Poland, ⁵Diagnostic-Consultative Center Aleksandrovska EOOD, Sofia, Bulgaria, ⁶ABK Reuma SRL, LIMA, Peru, ⁷Clinica Internacional Sede Lima, Lima, Peru, ⁸Dr. Bugyi István Hospital, Szentes, Hungary, ⁹Celltrion, Inc., Incheon, Republic of Korea
Background/Purpose: In the analysis of PLANETRA, a Phase III randomized controlled trial (RCT), no significant association was found between body mass index (BMI) and clinical…
Abstract Number: 284 • 2019 ACR/ARP Annual Meeting
Impact of Body Mass Index on the Agreement Between Ultrasound- and Clinical Assessments of Disease Activity in Rheumatoid Arthritis : Multicenter and Cross-sectional Study
Gaël Mouterde¹, Federico Manna ², Benoît Le Goff ³, Jean-David Albert ⁴, Sandrine Jousse-Joulin ⁵, Frédérique Gandjbakhch ⁶, Damien Loeuille ⁷, Philippe Gaudin ⁸, Muriel Piperno ⁹, Frédéric Banal ¹⁰, Bénédicte Jamard ¹¹, Carine Salliot ¹², Nicolas Molinari ², Bernard Combe ¹³, Maria-Antonietta D'Agostino ¹⁴ and Cédric Lukas ¹⁵, ¹CHU Montpellier and Univ Montpellier, Montpellier, France, ²Clinical Research and Epidemiology Unit, University Hospital, Montpellier, France, ³Rheumatology Department, CHU de Nantes and INSERM UMR 1238, Faculty of Biology of Nantes, Nantes, France, ⁴Rheumatology department, Rennes University Hospital and Institut NUMECAN, INSERM U 1241, Rennes, Bretagne, France, ⁵Rheumatology Department, Cavale Blanche Hospital and Brest Occidentale University, Brest, France, ⁶Rheumatology department, Pitié Salpêtrière hospital, APHP and Sorbonne University, Paris, France, ⁷Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France, ⁸Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, ⁹Rheumatology Department, Hospices Civils de Lyon, centre hospitalier Lyon Sud, Pierre Bénite, France, ¹⁰Service rhumatologie, hôpital d'instruction des armées Bégin, Saint Mandé, France, ¹¹Department of Rheumatology, Purpan Teaching Hospital, Toulouse, France, ¹²Rheumatology Unit, centre hospitalier regional d'Orleans, Orléans, France, ¹³CHU Montpellier, Montpellier University, Montpellier, France, ¹⁴UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne Billancourt, France, ¹⁵Rheumatology department, CHU Montpellier, Univ Montpellier, Montpellier, France
Background/Purpose: Clinical evaluation of synovitis in rheumatoid arthritis (RA) is difficult in obese (O) and overweight patients, due to the fat pad located around the…
Abstract Number: 1562 • 2019 ACR/ARP Annual Meeting
The Association of Body Weight Fluctuation and All-Cause Mortality in Patients with Systemic Lupus Erythematosus
Sarah Bayefsky¹, Alyson Dickson ¹, Tyler Reese ¹, Jocelyn Gandelman ², Megan Shuey ¹, April Barnado ¹, Katherine Barker ¹, C. Michael Stein ¹, Vivian Kawai ¹ and Cecilia Chung ¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University School of Medicine, Nashville, TN
Background/Purpose: Recent studies have suggested that body weight fluctuation in the general population is an independent risk factor for overall mortality. These findings are of…
Abstract Number: 2068 • 2019 ACR/ARP Annual Meeting
Body Mass Index and Systemic Corticosteroid Use as Indicators of Disease Burden and Their Influence on the Safety Profile of Certolizumab Pegol Across Indications
Vivian Bykerk¹, Andrew Blauvelt ², Jeffrey Curtis ³, Cécile Gaujoux-Viala ⁴, Tore K. Kvien ⁵, William J. Sandborn ⁶, Kevin Winthrop ⁷, Christina Popova ⁸ and Xavier Mariette ⁹, ¹Hospital for Special Surgery, New York City, NY, ²Oregon Medical Research Center, Portland, OR, USA, Portland, OR, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Nîmes University Hospital, Nîmes, France, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶University of California, La Jolla, CA, ⁷Oregon Health and Science University, Portland, OR, ⁸UCB Pharma, Brussels, Belgium, ⁹Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: Certolizumab pegol (CZP) is an anti-TNF drug approved for rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis (PSO) and Crohn’s disease (CD).…
Abstract Number: 2195 • 2019 ACR/ARP Annual Meeting
BMI Has Minimal Effect on Reduction of Symptoms in Patients with Osteoarthritis of the Knee Treated with Diclofenac 1% Gel
Joel A. Block¹, Bharat Patel ² and Sandy Yacoub Garas ³, ¹Rush University Medical Center, Chicago, IL, ²GlaxoSmithKline Consumer Healthcare, Weybridge, United Kingdom, ³GlaxoSmithKline Consumer Healthcare, Warren, NJ
Background/Purpose: Clinical trials demonstrate that diclofenac sodium gel 1% (DSG 1%), a topical NSAID, provides significantly better pain relief than vehicle placebo for patients with…
Abstract Number: 2601 • 2019 ACR/ARP Annual Meeting
Trabecular Bone Score and Malnutrition in a Cohort of Systemic Sclerosis Patients
Massimo Patane' ¹, Sabrina Paolino ¹, Veronica Tomatis ², Andrea Casabella ³, Carmen Pizzorni ¹, Luca Carmisciano ⁴, Alessio Signori ⁴ and Maurizio Cutolo⁵, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic Hospital San Martino, University of Genoa, Genoa, Italy.2Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy, genova, Liguria, Italy, ³1 Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁴Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by microvascular damage, immune system activation and progressive fibrosis of the skin and internal organs.…
Abstract Number: 2827 • 2019 ACR/ARP Annual Meeting
Weight Fluctuation and Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis
Joshua Baker¹, George Reed ² and Joel Kremer ³, ¹University of Pennsylvania, Philadelphia, PA, ²Corrona Research Foundation, Waltham, MA, ³Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Fluctuations in weight (weight cycling) occur in rheumatoid arthritis (RA) in association with severe disease features and comorbidity. In the general population, weight fluctuation…
Abstract Number: 2314 • 2018 ACR/ARHP Annual Meeting
Ratio of BMI to BMD at Different Sites and Association with Fragility Fractures
Marco Massarotti¹ and Marwan Bukhari², ¹Rheumatology, Royal Lancaster Infirmary, University Hospital of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom
Background/Purpose: Low body mass index (BMI)is linked to increase risk for osteoporosis , and fragility fractures and is therefore included in most fracture prediction…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].